Comparison of total hip arthroplasty with minimally invasive SuperPath approach vs. conventional posterolateral approach in elderly patients: A one-year follow-up randomized controlled research
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2021;9(7):7 Asian J Surg. 2021 Mar;44(3): 531-536.What this means for my practice?
Study findings suggest that using the supercapsular percutaneously-assisted total hip (SuperPath) approach compared to the conventional approach in total hip arthroplasty for treating patients with femoral neck fractures or ischemic necrosis of femoral statistically significantly improves acute post-operative pain and hip function. Moreover, this approach may improve gait and reduce inflammation post-surgery, while also reducing intraoperative blood loss and hospital length of stay. However, this study was limited by the small sample size of 96 patients total and lack of clarity regarding blinding practices. Therefore, future randomized controlled trials with larger sample size of patients and a clearly reported blinding methodology are needed to help confirm the findings of this study.
Zusammenfassung der Studie
Ninety-six elderly patients (≥65 years old) diagnosed with either a femoral neck fracture or ischemic necrosis of femoral head who were scheduled for a total hip arthroplasty were randomized to receive either the supercapsular percutaneously-assisted total hip (SuperPath) approach (n=49) or the conventional posterolateral approach (n=47). Outcomes of interest included pain evaluated using the Visual Analogue Scale (VAS), hip function using the Harris Hip Score (HHS), C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), creatine phosphokinase (CK) levels, peri-operative blood loss, incision length, operative time, hospital length of stay, step length, stride speed and frequency. VAS and HHS scores were measured at 7 days, 1 month, 3 months, 6 months, and 1-year post-surgery. CRP, ESR, and CK levels were measured at 3 days post-surgery. Finally, step length, stride frequency, and stride speed were measured at 1 and 3 months post-surgery. Results demonstrated that incision length, hospital length of stay, mean blood loss were all statistically significantly reduced in the SuperPath approach group vs. the conventional group (p<0.001 for all); yet, the SuperPath approach took statistically significantly longer for operative time compared to the conventional approach (p<0.001). Furthermore, VAS and HHS scores were statistically significantly improved in the SuperPath group at 7 days and 1 month post-surgery, as well as 3 months post-surgery for HHS scores (p<0.05 for all). In addition, CRP and CK levels were statistically significantly lower in the SuperPath approach group compared to the conventional group at 3-days post-surgery (p<0.001 for both); ESR was similar between the two groups (p=0.515). Finally, step length and stride speed were statistically significantly improved in the SuperPath group at 7 days and 1 month post-intervention, but this did not extend to 3 months nor was this difference observed for stride frequency at any of the timepoints (p>0.05). Two cases of joint dislocation were observed in the conventional group while none were observed for the SuperPath group. The angles of abduction were also statistically significantly lower in the SuperPath group (p<0.05), but no statistical significant difference was observed for the angle of anteversion between the 2 groups (p>0.05).
Vollständigen ACE-Bericht freischalten
Sie haben Zugang zu 4 weiteren KOSTENLOSEN Artikeln in diesem Monat.
Klicken Sie unten, um diese ACE Reports freizuschalten und anzusehen
Jetzt freischalten
Kritische Beurteilungen der neuesten, hochwirksamen randomisierten kontrollierten Studien und systematischen Übersichten in der Orthopädie
Zugang zu OrthoEvidence-Podcast-Inhalten, einschließlich Kooperationen mit dem Journal of Bone and Joint Surgery, Interviews mit international anerkannten Chirurgen und Diskussionsrunden zu orthopädischen Neuigkeiten und Themen
Abonnement von The Pulse, einem zweimal wöchentlich erscheinenden evidenzbasierten Newsletter, der Ihnen helfen soll, bessere klinische Entscheidungen zu treffen
Exklusiver Zugang zu Originalartikeln, einschließlich eigener systematischer Übersichten, sowie zu Artikeln über Methoden der Gesundheitsforschung und aktuelle orthopädische Themen
Oder upgraden Sie noch heute und erhalten Sie Zugang zu allen OrthoEvidence-Inhalten für nur $1,99 pro Woche.
Sie haben bereits ein Konto? Einloggen
Gehören Sie zu einem unserer Partnerverbände?
Klicken Sie hier, um im Rahmen Ihrer Verbandsmitgliedschaft kostenlosen Zugang zu erhalten!